Profuse oral secretions after propafenone administration in neonates.
Propafenone, an antiarrhythmic drug that is effective for treating supraventricular tachycardias, can induce well-known proarrhythmic and systemic adverse effects. We describe a previously unreported adverse effect in 3 newborns: oral propafenone-induced profuse oral secretions and respiratory distress of sufficient severity to necessitate discontinuation of propafenone.
Piersigilli
Fiammetta
F
Department of Neonatology, Bambino Gesù Children's Hospital, Rome, Italy. piersigilli@opbg.net
Auriti
Cinzia
C
Silvetti
Massimo Stefano
MS
Marrocco
Gabriella
G
Drago
Fabrizio
F
Seganti
Giulio
G
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D012634:Bodily Secretions; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009055:Mouth; D011405:Propafenone / Q000009:adverse effects*; D012127:Respiratory Distress Syndrome, Newborn / Q000139:chemically induced*; D012720:Severity of Illness Index
D000889:Anti-Arrhythmia Agents; D011405:Propafenone